Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Biometrics

Health Technology

Genetics

Pharmaceutical

Biotechnology

QIAGEN

More Like This

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland

PR Newswire associated0

MGI Tech and SeqOne Partner to Advance End-to-end Genomic Analysis